See more : JILIN JINGUAN ELECTRIC Co.,Ltd (300510.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Imugene Limited (IUGNF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Imugene Limited, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Rambus Inc. (0QYL.L) Income Statement Analysis – Financial Results
- Look Holdings Incorporated (8029.T) Income Statement Analysis – Financial Results
- Cauldron Energy Limited (CAULF) Income Statement Analysis – Financial Results
- Scancell Holdings plc (SCNLF) Income Statement Analysis – Financial Results
- AstraZeneca Pharma India Limited (ASTRAZEN.BO) Income Statement Analysis – Financial Results
Imugene Limited (IUGNF)
About Imugene Limited
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 11.78M | 12.97M | 7.23M | 4.13M | 4.13M | 1.84M | 1.16M | 1.56M | 638.68K | 538.31K | 207.22K | 235.91K | 2.23M | 0.00 | 0.00 | 0.00 | 374.56K | 0.00 | 0.00 | 0.00 | 19.00 | 1.29M | 114.24K | 0.00 | 0.00 | 0.00 | 3.86M | 278.00K | 188.00K | 0.00 | 0.00 |
| Cost of Revenue | 5.84M | 2.20M | 2.41M | 1.96M | 82.50K | 63.26K | 2.68K | 1.74K | 1.16K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 175.00K | 107.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -5.84M | 9.57M | 10.56M | 5.27M | 4.05M | 4.06M | 1.84M | 1.16M | 1.56M | 638.68K | 538.31K | 207.22K | 235.91K | 2.23M | 0.00 | 0.00 | 0.00 | 374.56K | 0.00 | 0.00 | 0.00 | 19.00 | 1.12M | 7.04K | 0.00 | 0.00 | 0.00 | 3.86M | 278.00K | 188.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 81.29% | 81.44% | 72.86% | 98.00% | 98.47% | 99.85% | 99.85% | 99.93% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 86.45% | 6.17% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 86.89M | 30.86M | 36.61M | 15.36M | 9.36M | 7.61M | 4.15M | 2.47M | 2.70M | 1.67M | 469.46K | 603.32K | 285.44K | 491.69K | 522.34K | 466.48K | 1.32M | 1.08M | 845.02K | 810.38K | 885.79K | 943.96K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 17.77M | 12.10M | 9.44M | 4.29M | 3.81M | 1.21M | 894.06K | 1.09M | 875.05K | 762.51K | 1.08M | 572.11K | 1.05M | 976.87K | 1.69M | 853.93K | 1.14M | 568.12K | 972.27K | 784.11K | 548.16K | 0.00 | 1.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 506.52K | 334.90K | 154.85K | 282.34K | 426.25K | 0.00 | 318.69K | 479.26K | 340.97K | 42.01K | 51.31K | 0.00 | 0.00 | 0.00 | 197.79K | 38.21K | 0.00 | 0.00 | 247.50K | 249.78K | 0.00 | 0.00 | 562.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 48.21M | 18.22M | 12.43M | 9.59M | 4.58M | 4.23M | 1.21M | 894.06K | 1.09M | 875.05K | 804.53K | 1.14M | 572.11K | 1.05M | 976.87K | 1.69M | 853.93K | 1.14M | 568.12K | 1.22M | 1.03M | 548.16K | 0.00 | 1.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 11.53M | 12.84M | 7.20M | 4.07M | 4.21M | 1.75M | 1.14M | 1.50M | 679.52K | 883.99K | 156.66K | 114.50K | -171.66K | 312.12K | 3.17M | 340.63K | 372.99K | 169.77K | 254.77K | 43.00K | 509.06K | -466.00K | -1.30M | -4.40M | -4.90M | -4.52M | -3.86M | 593.00K | 747.00K | 766.00K | 262.00K |
| Operating Expenses | 135.09M | 49.09M | 50.67M | 25.67M | 14.88M | 12.39M | 5.78M | 3.69M | 4.27M | 2.88M | 1.34M | 1.74M | 1.40M | 1.89M | 2.12M | 2.76M | 2.56M | 3.04M | 3.15M | 2.51M | 2.44M | 2.43M | 328.00K | 2.58M | -4.40M | -4.90M | -4.52M | 1.39M | 871.00K | 935.00K | 766.00K | 262.00K |
| Cost & Expenses | 140.93M | 51.29M | 50.67M | 25.67M | 14.88M | 12.39M | 5.78M | 3.69M | 4.27M | 2.88M | 1.34M | 1.74M | 1.40M | 1.89M | 2.12M | 2.76M | 2.56M | 3.04M | 3.15M | 2.51M | 2.44M | 2.43M | 503.00K | 2.69M | -4.40M | -4.90M | -4.52M | 1.39M | 871.00K | 935.00K | 766.00K | 262.00K |
| Interest Income | 4.52M | 1.88M | 192.25K | 126.57K | 302.19K | 414.89K | 94.33K | 35.43K | 39.40K | 38.36K | 27.10K | 23.21K | 8.68K | 10.25K | 44.02K | 76.61K | 67.21K | 101.69K | 196.56K | 134.73K | 80.60K | 29.47K | 12.00K | 8.32K | 0.00 | 0.00 | 0.00 | 59.00K | 14.00K | 133.00K | 79.00K | 0.00 |
| Interest Expense | 478.36K | 27.45K | 106.74K | 111.03K | 5.03K | 6.11K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 180.95K | 18.00K | 27.00K | 28.00K | 68.00K | 97.00K | 0.00 | 33.00K | 23.00K |
| Depreciation & Amortization | 5.84M | 2.20M | 2.41M | 1.96M | 82.50K | 63.26K | 2.68K | 1.74K | 1.16K | 2.25M | 676.00 | 676.00 | 172.11K | 343.15K | 343.01K | 343.18K | 343.85K | 345.71K | 346.65K | 347.67K | 348.59K | 132.23K | 328.00K | 439.64K | 0.00 | 0.00 | 0.00 | 572.00K | 581.00K | 491.00K | 328.00K | 163.00K |
| EBITDA | -135.09M | -37.26M | -37.45M | -18.24M | -10.42M | -7.71M | -5.78M | -3.68M | -4.27M | -194.89K | -796.82K | -1.74M | -995.33K | 682.09K | -1.78M | -2.41M | -2.22M | -2.69M | -2.81M | -2.17M | -1.62M | -2.30M | -770.00K | -3.42M | -4.40M | -4.90M | -4.52M | -2.11M | -4.15M | -1.51M | -871.00K | -305.00K |
| EBITDA Ratio | 0.00% | -416.80% | -288.78% | -252.23% | -252.08% | -186.70% | -313.88% | -316.56% | -272.82% | -408.73% | 66.03% | -839.09% | 463.67% | 30.63% | 0.00% | 0.00% | 0.00% | -619.88% | 0.00% | 0.00% | 0.00% | -12,085,773.68% | -59.61% | -2,994.51% | 0.00% | 0.00% | 0.00% | -54.78% | -1,491.73% | -804.79% | 0.00% | 0.00% |
| Operating Income | -140.93M | -51.29M | -37.66M | -18.34M | -10.50M | -7.77M | -5.78M | -3.69M | -4.27M | -2.61M | 355.45K | -1.74M | 921.74K | 338.94K | -2.12M | -2.76M | -2.56M | -2.67M | -3.15M | -2.51M | -1.97M | -2.43M | -1.10M | -3.86M | -4.40M | -4.90M | -4.52M | -2.69M | -4.73M | -2.00M | -1.20M | -468.00K |
| Operating Income Ratio | 0.00% | -435.51% | -290.35% | -253.67% | -254.07% | -188.23% | -314.03% | -316.71% | -272.89% | -408.73% | 66.03% | -839.41% | 390.71% | 15.22% | 0.00% | 0.00% | 0.00% | -712.18% | 0.00% | 0.00% | 0.00% | -12,781,710.53% | -85.00% | -3,379.35% | 0.00% | 0.00% | 0.00% | -69.60% | -1,700.72% | -1,065.96% | 0.00% | 0.00% |
| Total Other Income/Expenses | -13.37M | 1.60M | -165.91K | -20.76K | 237.35K | 486.39K | 3.50K | 14.28K | -26.10K | -194.89K | -1.32M | -27.35K | -1.97M | -159.40K | 358.00K | 3.01M | 410.55K | 106.26K | 712.98K | 396.03K | -819.82K | 384.41K | -1.57M | -180.95K | -18.41K | -27.00K | -28.00K | -6.04M | -3.65M | -766.00K | 295.00K | 140.00K |
| Income Before Tax | -154.30M | -49.66M | -37.87M | -18.46M | -10.51M | -7.78M | -3.93M | -2.51M | -2.73M | -2.44M | -2.12M | -1.56M | -3.13M | 179.54K | -1.77M | 252.50K | -2.15M | -2.56M | -2.44M | -2.12M | -2.79M | -2.04M | -782.00K | -4.04M | -4.42M | -4.93M | -4.55M | -2.18M | -4.24M | -1.51M | -904.00K | -328.00K |
| Income Before Tax Ratio | 0.00% | -421.62% | -291.98% | -255.21% | -254.19% | -188.39% | -213.69% | -215.33% | -174.56% | -382.16% | -393.07% | -752.61% | -1,328.22% | 8.06% | 0.00% | 0.00% | 0.00% | -683.81% | 0.00% | 0.00% | 0.00% | -10,758,515.79% | -60.54% | -3,537.75% | 0.00% | 0.00% | 0.00% | -56.54% | -1,526.62% | -804.79% | 0.00% | 0.00% |
| Income Tax Expense | -4.62M | -11.74M | 12.94M | 7.31M | 4.08M | 4.21M | -97.01K | -37.17K | -39.40K | -2.01M | 1.66M | -23.21K | 2.08M | -236.00K | -230.00K | -397.79K | -238.74K | -257.05K | -252.06K | -2.12M | -2.79M | -2.04M | -782.00K | -4.04M | -4.42M | -4.93M | -4.55M | -2.18M | -4.24M | -1.51M | -904.00K | -328.00K |
| Net Income | -149.68M | -37.91M | -37.87M | -18.46M | -10.51M | -7.78M | -3.93M | -2.51M | -2.73M | -2.44M | -2.12M | -1.56M | -3.13M | 415.54K | -1.54M | 650.29K | -1.91M | -2.30M | -2.19M | -1.79M | -2.12M | 699.06K | -782.00K | -4.04M | -4.42M | -4.93M | -4.55M | -2.18M | -4.24M | -2.14M | -875.00K | 243.00K |
| Net Income Ratio | 0.00% | -321.92% | -291.98% | -255.21% | -254.19% | -188.39% | -213.69% | -215.33% | -174.56% | -382.16% | -393.07% | -752.61% | -1,328.22% | 18.66% | 0.00% | 0.00% | 0.00% | -615.19% | 0.00% | 0.00% | 0.00% | 3,679,200.00% | -60.54% | -3,537.75% | 0.00% | 0.00% | 0.00% | -56.54% | -1,526.62% | -1,135.64% | 0.00% | 0.00% |
| EPS | -0.02 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 | -0.01 | 0.00 | -0.01 | -0.02 | -0.02 | -0.01 | -0.02 | -0.02 | -0.04 | -1.60 | -1.84 | -2.27 | -2.35 | -1.37 | -2.92 | -1.53 | -0.83 | 0.34 |
| EPS Diluted | -0.02 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 | -0.01 | 0.00 | -0.01 | -0.02 | -0.02 | -0.01 | -0.02 | -0.02 | -0.04 | -1.60 | -1.84 | -2.27 | -2.35 | -1.37 | -2.92 | -1.53 | -0.83 | 0.34 |
| Weighted Avg Shares Out | 7.09B | 6.28B | 5.64B | 4.66B | 4.07B | 3.58B | 2.64B | 2.09B | 1.33B | 1.19B | 695.41M | 327.84M | 144.93M | 144.93M | 144.93M | 144.93M | 137.66M | 132.17M | 132.17M | 121.58M | 109.03M | 71.24M | 21.14M | 2.52M | 2.40M | 2.17M | 1.94M | 1.59M | 1.45M | 1.40M | 1.05M | 292.05K |
| Weighted Avg Shares Out (Dil) | 7.09B | 6.28B | 5.64B | 4.66B | 4.07B | 3.58B | 2.64B | 2.09B | 1.33B | 1.19B | 695.41M | 327.84M | 144.93M | 144.93M | 144.93M | 164.04M | 137.66M | 132.17M | 132.17M | 121.58M | 109.03M | 71.24M | 21.14M | 2.52M | 2.40M | 2.17M | 1.94M | 1.59M | 1.45M | 1.40M | 1.05M | 292.05K |
Imugene ends June 2021 quarter with $29.5m cash balance and strong focus on research and development
Imugene Limited (ASX:IMU) (OTCMKTS:IUGNF) is well-funded and ready to progress to human studies for its CF33 and PD1-Vaxx treatments in the near-term as well as continuing enrolment into the HER-Vaxx phase two study. In September the company boosted its balance sheet...
Imugene enters into strategic partnership with Celularity to develop immunotherapy for solid tumors
Imugene Ltd has entered into a research collaboration with Celurlarity Inc to develop a novel oncolytic virus allogeneic CAR T-Cell immunotherapy combination for the treatment of solid tumors. As part of the partnership, Imugene and Celularity will initially collaborate to...
Source: https://incomestatements.info
Category: Stock Reports